INDV
HealthcareIndivior PLC
$36.25
+$0.52 (+1.46%)
Jan 5, 2026
Price History (1Y)
Analysis
Indivior PLC is a healthcare company operating in the drug manufacturers - specialty & generic industry. With a market capitalization of $4.53 billion and revenue of $1.18 billion (TTM), the company has a significant presence in its sector. Indivior employs approximately 1030 individuals, indicating a moderate scale. The financial health of Indivior is characterized by substantial profitability. The company's gross margin stands at 83.8%, while its operating and profit margins are 36.9% and 10.5%, respectively (TTM). Return on assets is reported as 13.1%. On the balance sheet, cash reserves amount to $445.00 million, with debt totaling $356.00 million. The current ratio is 0.95. Valuation metrics indicate a mix of relatively high and low multiples for Indivior. With a P/E ratio (TTM) of 36.62 and forward P/E of 12.54, the company's valuation appears to be influenced by its growth prospects. Revenue growth has been moderate at 2.3% YoY, while earnings growth is significantly higher at 106.3%. The dividend yield is not applicable due to the absence of a payout ratio (0.0%).
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Indivior PLC
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). The company also offers OPVEE nasal spray for opioid overdose reversal. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Visit website →Key Statistics
- Market Cap
- $4.53B
- P/E Ratio
- 36.62
- 52-Week High
- $38.00
- 52-Week Low
- $7.62
- Avg Volume
- 2.46M
- Beta
- 1.10
Company Info
- Exchange
- NMS
- Country
- United States
- Employees
- 1,030